Abbott Laboratories Stock Forecast, Price & News

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 1 sell rating, 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Abbott Laboratories stock.
View analyst ratings for Abbott Laboratories or view top-rated stocks.

Wall Street analysts have given Abbott Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abbott Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Abbott Laboratories saw a increase in short interest in January. As of January 29th, there was short interest totaling 11,520,000 shares, an increase of 29.4% from the January 14th total of 8,900,000 shares. Based on an average daily trading volume, of 5,100,000 shares, the days-to-cover ratio is presently 2.3 days.
View Abbott Laboratories' Short Interest.

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, April 15th 2021.
View our earnings forecast for Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) posted its earnings results on Tuesday, January, 26th. The healthcare product maker reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.35 by $0.10. The healthcare product maker had revenue of $10.70 billion for the quarter, compared to analyst estimates of $9.94 billion. Abbott Laboratories had a trailing twelve-month return on equity of 18.19% and a net margin of 10.50%. The company's revenue for the quarter was up 28.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.95 EPS.
View Abbott Laboratories' earnings history.

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABT shares have increased by 55.7% and is now trading at $121.58.
View which stocks have been most impacted by COVID-19.

Abbott Laboratories declared a quarterly dividend on Friday, February 19th. Stockholders of record on Thursday, April 15th will be given a dividend of $0.45 per share on Monday, May 17th. This represents a $1.80 annualized dividend and a dividend yield of 1.48%. The ex-dividend date is Wednesday, April 14th.
View Abbott Laboratories' dividend history.

Abbott Laboratories pays an annual dividend of $1.80 per share and currently has a dividend yield of 1.47%. Abbott Laboratories has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Abbott Laboratories is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.10% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.
View Abbott Laboratories' dividend history.

Abbott Laboratories updated its FY21 earnings guidance on Wednesday, January, 27th. The company provided EPS guidance of at least $5.00 for the period, compared to the Thomson Reuters consensus estimate of $4.42.

17 equities research analysts have issued 1-year price objectives for Abbott Laboratories' stock. Their forecasts range from $94.00 to $140.00. On average, they expect Abbott Laboratories' share price to reach $121.83 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price.
View analysts' price targets for Abbott Laboratories or view top-rated stocks among Wall Street analysts.

183 employees have rated Abbott Laboratories CEO Robert Ford on Glassdoor.com. Robert Ford has an approval rating of 89% among Abbott Laboratories' employees.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), Varian Medical Systems (VAR) and STERIS (STE).
View all of ABT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), The Home Depot (HD) and Verizon Communications (VZ).

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.53%), Morgan Stanley (1.51%), Northern Trust Corp (1.49%), Bank of New York Mellon Corp (1.20%), Wells Fargo & Company MN (1.13%) and FMR LLC (1.02%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Michelle Kumbier, Miles D White, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Boston Partners, Boston Partners, Sumitomo Mitsui Trust Holdings Inc., Fort Pitt Capital Group LLC, DSM Capital Partners LLC, and Northern Trust Corp. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael J Pederson, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories or view top insider-selling stocks.

ABT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Assenagon Asset Management S.A., Healthcare of Ontario Pension Plan Trust Fund, Amundi Pioneer Asset Management Inc., Swedbank, First Trust Advisors LP, and Bank of New York Mellon Corp. Company insiders that have bought Abbott Laboratories stock in the last two years include Michelle Kumbier, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories or or view top insider-buying stocks.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABT stock can currently be purchased for approximately $121.58.

Abbott Laboratories has a market capitalization of $215.38 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis.

Abbott Laboratories employs 107,000 workers across the globe.

The official website for Abbott Laboratories is www.abbott.com.

Abbott Laboratories is headquartered at 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.